西格列汀联合胰岛素强化治疗对2型糖尿病早期大血管病变的保护作用机制分析

Protective mechanism of sitagliptin combined with intensive insulin therapy on early macroangiopathy diseasein type 2 diabetes mellitus

目的探究西格列汀联合胰岛素强化治疗对2型糖尿病早期大血管病变的保护作用机制。方法选取2019年7月至2021年12月本院收治的60例2型糖尿病早期大血管病变患者作为研究对象,按照入院先后顺序分为参照组(应用胰岛素强化治疗)与研究组(应用西格列汀联合胰岛素强化治疗),每组30例。比较两组治疗前后相关血糖[空腹血糖(FBG)和餐后2 h血糖(2 h PBG)]、血脂[三酰甘油(TG)和总胆固醇(TC)]及炎症因子[同型半胱氨酸(Hcy)和C反应蛋白(CRP)]水平变化情况。结果治疗前,两组FBG、2 h PBG、TG、TC、Hcy和CRP水平比较差异无统计学意义;治疗后,研究组FBG、2 h PBG、TG、TC、Hcy和CRP水平均低于参照组,差异有统计学意义(P<0.05)。结论西格列汀联合胰岛素强化治疗2型糖尿病早期大血管病变效果显著,更有利于调节患者血糖、血脂水平,从而降低炎症因子水平,达到保护大血管的目的,值得临床推广应用。

Objective To explore the protective mechanism of sitagliptin combined with intensive insulin therapy on early macrovascular diseasein type 2 diabetes mellitus.Methods 60 patients with type 2 diabetes mellitus with early macrovascular disease who were admitted to our hospital from July 2019 to December 2021 were selected as the research subjects,they were divided into reference group(intensive insulin therapy)and research group(sitagliptin combined with intensive insulin therapy)according to the order of admission,with 30 cases in each group.The related blood glucose(fasting blood glucose[FBG]and 2 h postprandial blood glucose[2 h PBG]),blood lipid(triglyceride[TG]and total cholesterol[TC])and inflammatory factors(homocysteine[Hcy]and C-reactive protein[CRP])before and after treatment were compared between the two groups.Results Before treatment,there was no significant difference in the levels of FBG,2 h PBG,TG,TC,Hcy and CRP between the two groups;after treatment,the levels of FBG,2 h PBG,TG,TC,Hcy and CRP in the study group were lower than those of the reference group group,the difference was statistically significant(P<0.05).Conclusion Sitagliptin combined with insulin has significant effect in the treatment of early macrovascular diseasein type 2 diabetes,and is more conducive to regulating the levels of blood sugar and blood lipids in patients,thereby reducing the level of inflammatory factors,thereby achieving the purpose of protecting macrovascular disease,which is worthy of clinical application.